Page last updated: 2024-08-24

triazoles and empagliflozin

triazoles has been researched along with empagliflozin in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brand, T; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ1
Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ1
Scheen, AJ1
Broedl, UC; Delafont, B; Eilbracht, J; Kim, G; Roden, M; Weng, J; Woerle, HJ1
Cornell, S1

Reviews

1 review(s) available for triazoles and empagliflozin

ArticleYear
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
    Postgraduate medicine, 2015, Volume: 127, Issue:3

    Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss

2015

Trials

3 trial(s) available for triazoles and empagliflozin

ArticleYear
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Advances in therapy, 2012, Volume: 29, Issue:10

    Topics: Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles

2012
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles

2013
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2013, Volume: 1, Issue:3

    Topics: Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles

2013

Other Studies

1 other study(ies) available for triazoles and empagliflozin

ArticleYear
SGLT2 versus DPP4 inhibitors for type 2 diabetes.
    The lancet. Diabetes & endocrinology, 2013, Volume: 1, Issue:3

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles

2013